Jonathan M. Backer < Jonathan M. Brotchie < Jonathan M. Wastling

Facettes :

List of bibliographic references indexed by Jonathan M. Brotchie

Number of relevant bibliographic references: 57.
[0-50] [0 - 20][0 - 50][50-56][50-70]

Ident.	Authors (with country if any)	Title
000127 (2017)	Chi Wang Ip [Allemagne] ; Laura-Christin Klaus [Allemagne] ; Akua A. Karikari [Allemagne] ; Naomi P. Visanji ; Jonathan M. Brotchie ; Anthony E. Lang ; Jens Volkmann [Allemagne] ; James B. Koprich	AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
000138 (2016)	Naomi P. Visanji [Canada] ; Jonathan M. Brotchie [Canada] ; Lorraine V. Kalia [Canada] ; James B. Koprich [Canada] ; Anurag Tandon [Canada] ; Joel C. Watts [Canada] ; Anthony E. Lang [Canada]	α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
000153 (2016)	Qing He [République populaire de Chine] ; James B. Koprich [Canada] ; Ying Wang [République populaire de Chine] ; Wen-Bo Yu [République populaire de Chine] ; Bao-Guo Xiao [République populaire de Chine] ; Jonathan M. Brotchie [Canada] ; Jian Wang [République populaire de Chine]	Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
000157 (2016)	James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; Gabriela Reyes [Canada] ; Vanessa Omana [Canada] ; Jonathan M. Brotchie [Canada]	Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
000551 (2015)	Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada]	Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
000641 (2015)	Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]	Monoamine Reuptake Inhibitors in Parkinson's Disease
000719 (2015)	Sujoy Phookan [États-Unis] ; Alexander C. Sutton [États-Unis] ; Ian Walling [États-Unis] ; Autumn Smith [États-Unis] ; Katherine A. O'Connor [États-Unis] ; Joannalee C. Campbell [États-Unis] ; Megan Calos [États-Unis] ; Wilson Yu [États-Unis] ; Julie G. Pilitsis [États-Unis] ; Jonathan M. Brotchie [Canada] ; Damian S. Shin [États-Unis]	Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats.
000877 (2014)	Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]	UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
000933 (2014)	Sherri L. Thiele [Canada] ; Betty Chen [Canada] ; Charlotte Lo [Canada] ; Tracey S. Gertler [États-Unis] ; Ruth Warre [Canada] ; James D. Surmeier [États-Unis] ; Jonathan M. Brotchie [Canada] ; Joanne E. Nash [Canada]	Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models
000C43 (2013)	Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. Brotchie	The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
000C50 (2013)	James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
000E88 (2013)	Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
000F09 (2013)	Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]	Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque
000F36 (2013)	Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert [États-Unis] ; Tacey X. Viegas [États-Unis] ; Michael D. Bentley [États-Unis] ; Zhihao Fang [États-Unis] ; Bekir Dizman [États-Unis] ; Kunsang Yoon [États-Unis] ; Rebecca Weimer [États-Unis] ; Paula Ravenscroft [Canada] ; Tom H. Johnston [Canada] ; Michael P. Hill [Canada] ; Jonathan M. Brotchie [Canada] ; Randall W. Moreadith [États-Unis]	Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
001005 (2013)	Alexander C. Sutton [États-Unis] ; Wilson Yu [États-Unis] ; Megan E. Calos [États-Unis] ; Lauren E. Mueller [États-Unis] ; Matthew Berk [États-Unis] ; Jenny Shim [États-Unis] ; Eric S. Molho [États-Unis] ; Jonathan M. Brotchie [Canada] ; Peter L. Carlen [Canada] ; Damian S. Shin [États-Unis]	Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat
001038 (2013)	James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada]	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
001116 (2012)	Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Michael N. Gandy [Australie] ; M. Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]	The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
001191 (2012)	Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. Brotchie	L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
001293 (2012)	Tom H. Johnston [Canada] ; Zak Millar ; Philippe Huot ; Keith Wagg ; Sherri Thiele ; Danielle Salomonczyk ; Christopher J. Yong-Kee ; Michael N. Gandy ; Matthew Mcildowie ; Katie D. Lewis ; Jordi Gomez-Ramirez ; Joohyung Lee ; Susan H. Fox ; Mathew Martin-Iverson ; Joanne E. Nash ; Matthew J. Piggott ; Jonathan M. Brotchie	A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
001413 (2012)	Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
001474 (2012)	Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Nègre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarié [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France]	A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease
001574 (2011)	Philippe Huot [Canada] ; Susan H. Fox ; Jonathan M. Brotchie	The serotonergic system in Parkinson's disease.
001608 (2011)	Ruediger Hilker [Allemagne] ; Jonathan M. Brotchie [Canada] ; Joab Chapman [Israël]	Pros and cons of a prion-like pathogenesis in Parkinson's disease
001610 (2011)	James B. Koprich ; Tom H. Johnston ; Philippe Huot ; M. Gabriela Reyes ; Maria Espinosa ; Jonathan M. Brotchie	Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
001723 (2011)	Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. Brotchie	Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
001743 (2011)	Philippe Huot [Canada] ; Jonathan M. Brotchie	5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.
001778 (2011)	James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada]	The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
001986 (2010)	Susan H. Fox [Canada] ; Jonathan M. Brotchie	The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
001996 (2010)	Tom H. Johnston [Canada] ; Susan H. Fox ; Matthew J. Mcildowie ; Matthew J. Piggott ; Jonathan M. Brotchie	Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
001A47 (2010)	James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; M Gabriela Reyes [Canada] ; Xuan Sun [Canada] ; Jonathan M. Brotchie [Canada]	Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
001B24 (2010)	Michael N. Gandy [Australie] ; Matthew Mcildowie [Australie] ; Katie Lewis [Australie] ; Agata M. Wasik [Royaume-Uni] ; Danielle Salomonczyk [Canada] ; Keith Wagg [Australie] ; Zak A. Millar [Australie] ; David Tindiglia [Australie] ; Philippe Huot [Canada] ; Tom Johnston [Canada] ; Sherri Thiele [Canada] ; Blake Nguyen [Australie] ; Nicholas M. Barnes [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Mathew T. Martin-Iverson [Australie] ; Joanne Nash [Canada] ; John Gordon [Royaume-Uni] ; Matthew J. Piggott [Australie]	Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity
001B51 (2010)	Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]	The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
001C09 (2010)	Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
001C36 (2010)	Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease
001C77 (2010)	Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]	The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates
001C89 (2010)	Susan H. Fox [Canada] ; Naomi Visanji [Canada] ; Gaby Reyes [Canada] ; Philippe Huot [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom Johnston [Canada] ; Jonathan M. Brotchie [Canada]	Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease
001D05 (2010)	Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations
001F59 (2009)	Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada]	Serotonin and Parkinson's disease: On movement, mood, and madness
002158 (2008)	Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. Brotchie	Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
002166 (2008)	Susan H. Fox [Canada] ; Jonathan M. Brotchie ; Anthony E. Lang	Non-dopaminergic treatments in development for Parkinson's disease.
002281 (2008)	Joohyung Lee [Canada, Australie] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi Visanji [Canada] ; Jonathan M. Brotchie [Canada]	Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease
002373 (2008)	Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease
002379 (2008)	Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis]	Striatal histone modifications in models of levodopa-induced dyskinesia
002565 (2007)	Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis]	Levodopa‐induced dyskinesias
002784 (2006)	Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada]	Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure
002813 (2006)	Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
002925 (2006)	Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]	Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease
002947 (2006)	Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada]	Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats
002A01 (2005)	Tom H. Johnston [Canada] ; Susan H. Fox ; Jonathan M. Brotchie	Advances in the delivery of treatments for Parkinson's disease.
002A41 (2005)	Jonathan M. Brotchie [Canada]	Nondopaminergic mechanisms in levodopa‐induced dyskinesia
002B32 (2005)	Katerina Venderov [Canada] ; Timothy M. Brown [Royaume-Uni] ; Jonathan M. Brotchie [Canada]	Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i -k "Jonathan M. Brotchie" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i  \
                -Sk "Jonathan M. Brotchie" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Author.i
   |clé=    Jonathan M. Brotchie
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022